Trial Profile
A phase III, randomized, double-blind, placebo-controlled study of the safety and efficacy of adefovir dipivoxil (Bis-POM PMEA) in prolonging survival of HIV-infected individuals with a CD4+ cell count of <=100/mm3 or with a CD4+ cell count both >100 and <= 200/mm3 and a nadir CD4+ cell count of <= 50/mm3
Status:
Completed
Phase of Trial:
Phase III
Latest Information Update: 03 Nov 2021
Price :
$35
*
At a glance
- Drugs Adefovir dipivoxil (Primary)
- Indications Cytomegalovirus infections; HIV infections
- Focus Therapeutic Use
- 25 Sep 2008 Actual start date (Dec 1996) added as reported by CT.gov
- 25 Sep 2008 Actual patient number (505) added as reported by CT.gov
- 25 Sep 2008 Planned end date (Jan 1999) added as reported by CT.gov